We conclude that the use of this specific p70S6K inhibitor hampers the onset of obesity and associated disturbances, such as the progression of fatty liver and hypertriglyceridemia, even though insulin sensitivity did not improve in our treated mice. This evidence concerns the gene RPS6KB1 and Hepatic steatosis.